How long Apatinib can extend life depends mainly on the condition of the primary disease treated with Apatinib. Apatinib is an anti-angiogenic targeted drug, which mainly inhibits tumor growth by inhibiting tumor angiogenesis, and it can treat malignant tumors such as gastric cancer, primary liver cancer, lung cancer and soft tissue tumors. For example, the median survival time of advanced gastric cancer is about one to two years; patients with primary liver cancer can extend their survival time by about three months to six months after taking Apatinib; and Apatinib is much more effective in the treatment of other soft tissue tumors than in gastric cancer and liver cancer. Currently, there are data showing that taking Apatinib can prolong progression-free survival for about six months to one year. Apatinib, as the only recommended drug for third-line treatment of gastric cancer, has been included in the negotiation of the national basic medical insurance, work injury insurance and maternity insurance drug catalog in 2017, and it provides a new treatment option for patients with advanced gastric cancer in China.